Development
Emergent BioSolutions Inc.
EBS
$8.92
$0.769.31%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -760.50M | -778.00M | -595.80M | -390.90M | -211.60M |
| Total Depreciation and Amortization | 125.10M | 118.50M | 135.40M | 134.30M | 130.60M |
| Total Amortization of Deferred Charges | 21.30M | 16.60M | 12.00M | 4.10M | 4.10M |
| Total Other Non-Cash Items | 478.10M | 448.90M | 253.90M | 32.20M | 44.90M |
| Change in Net Operating Assets | -70.30M | 48.40M | -85.10M | 39.50M | -2.10M |
| Cash from Operations | -206.30M | -145.60M | -279.60M | -180.80M | -34.10M |
| Capital Expenditure | -51.60M | -63.80M | -79.10M | -98.70M | -115.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 270.20M | 270.20M | 270.20M | -- | -- |
| Other Investing Activities | -6.30M | -28.10M | -265.50M | -265.50M | -265.50M |
| Cash from Investing | 212.30M | 178.30M | -74.40M | -364.20M | -381.30M |
| Total Debt Issued | 20.00M | 360.00M | 598.00M | 598.00M | 598.00M |
| Total Debt Repaid | -563.40M | -556.00M | -521.50M | -33.70M | -33.80M |
| Issuance of Common Stock | 10.20M | 11.50M | 11.50M | 4.50M | 5.00M |
| Repurchase of Common Stock | -2.50M | -2.80M | -3.00M | -27.60M | -88.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -535.70M | -187.30M | 85.00M | 541.20M | 481.20M |
| Foreign Exchange rate Adjustments | -1.20M | 1.40M | -700.00K | 600.00K | 500.00K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | -2.60M | -- |
| Net Change in Cash | -530.90M | -153.20M | -269.70M | -5.80M | 66.30M |